Elvinix Licenses Zealand Pharma's GLP-1/Gastrin Dual-Agonist Peptides for Beta-Cell Regeneration in Type 1 Diabetes
核心洞察
Elvinix Inc. (搜索) has secured an exclusive license from Zealand Pharma to develop and commercialize a GLP-1/gastrin dual-agonist peptide (搜索) portfolio for type 1 diabetes (搜索).
The company aims to advance the peptides as a potentially first-in-class, disease-modifying therapy that regenerates and protects endogenous insulin-producing beta cells.
The agreement grants Elvinix rights to the dual-agonist patent families plus an extensive preclinical data package, with the lead candidate still in preclinical development.
Elvinix Inc. (搜索), a biopharmaceutical company developing a regenerative, disease-modifying therapy for type 1 diabetes (搜索) (T1D), announced an exclusive license agreement with Zealand Pharma A/S (搜索) (Nasdaq Copenhagen: ZEAL) granting it the rights to develop and commercialize Zealand's GLP-1/gastrin dual-agonist peptide (搜索) portfolio. The Dover, Delaware-based company said it plans to advance the licensed peptides as a disease-modifying therapy intended to regenerate and protect endogenous beta-cell mass in patients with T1D.
Under the agreement, Elvinix gains an exclusive license to the GLP-1/gastrin dual-agonist patent families along with an extensive package of preclinical data, which the company described as a strong foundation for upcoming clinical development. Elvinix is currently in preclinical development and is planning to advance its lead candidate toward clinical studies.
Rationale for a Regenerative Approach
Approximately 9.5 million people worldwide live with T1D, a number that rises each year, according to the International Diabetes Federation's IDF Diabetes Atlas, 11th edition, and T1D Index Version 3.0 (2025), cited in the announcement. Elvinix is developing a novel, disease-modifying therapy designed to regenerate and protect insulin-producing beta cells. According to the company, restoring insulin secretion in people with T1D could decrease the risk of hypoglycemia and diabetic complications and reduce the burden of insulin therapy.
"This license gives us a peptide platform backed by years of rigorous preclinical work, freeing us to focus on what matters most: advancing a potentially first-in-class, disease-modifying therapy for type 1 diabetes (搜索)," said Daniil Koshelev, Chief Executive Officer of Elvinix. "Patients have waited a long time for treatments that can change the course of this disease, and this is a meaningful step toward delivering one."
Founding Team and Partner Profile
Elvinix was co-founded by a team that includes three experts in diabetes and metabolic medicine — Dr. Alex Rabinovitch, Dr. Jay Skyler, and Dr. Alexander Fleming — who together bring decades of experience spanning beta-cell biology, clinical diabetes research, and the development and regulation of metabolic therapies, the company said. Elvinix also expressed gratitude to the Zealand Pharma team for its support and expertise.
Zealand Pharma A/S (搜索) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company, founded in 1998 and headquartered in Copenhagen, Denmark, with a presence in the U.S., has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.
Development Status
Elvinix's product candidates remain investigational and have not been evaluated or approved by any regulatory authority, and the company noted they may not demonstrate safety or efficacy in clinical studies. The company is headquartered in Dover, Delaware.